Meta-Analysis
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Jun 27, 2025; 17(6): 106418
Published online Jun 27, 2025. doi: 10.4254/wjh.v17.i6.106418
Human albumin infusion for reducing hyponatremia and circulatory dysfunction in liver cirrhosis: A meta-analysis update
Hui-Juan Zhou, Zi-Qiang Li, Da-Er Dili, Qing Xie
Hui-Juan Zhou, Zi-Qiang Li, Qing Xie, Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
Da-Er Dili, Takeda (China) Holding Co., Ltd., Shanghai 200025, China
Co-first authors: Hui-Juan Zhou and Zi-Qiang Li.
Author contributions: Zhou HJ and Li ZQ contribute equally to this study as co-first authors; Zhou HJ and Li ZQ were responsible for study concept and design; Li ZQ was responsible for acquisition of data; Dili DE was responsible for analysis and interpretation of data; Dili DE and Xie Q were responsible for drafting of the manuscript; Zhou HJ was responsible for critical revision of the manuscript for important intellectual content; Dili DE was responsible for administrative, technical, or material support; Zhou HJ and Xie Q were responsible for study supervision; all authors have made a significant contribution to this study and have approved the final manuscript.
Supported by National Natural Science Foundation of China, No. 82070604 and No. 82270618; and the Shanghai Municipal Key Clinical Specialty, China, No. shslczdzk01103.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing Xie, PhD, Chief Physician, Full Professor, Department of Infectious Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197 Ruijin Second Road, Shanghai 200025, China. xieqingrjh@163.com
Received: February 27, 2025
Revised: April 15, 2025
Accepted: June 3, 2025
Published online: June 27, 2025
Processing time: 119 Days and 5 Hours
Core Tip

Core Tip: Liver cirrhosis is one of the leading causes of death worldwide, which imposes a substantial public health burden. The efficacy of various therapies, such as albumin infusion, volume expanders (VEs), and vasoactive drugs, used to treat patients with cirrhosis is still not clear. This meta-analysis compares albumin infusion, VEs, and vasoactive agents for the treatment of liver cirrhosis. Albumin infusion significantly decreases hyponatremia and paracentesis induced circulatory dysfunction compared to other treatments. These findings indicate that albumin therapy is more effective against complications of liver cirrhosis compared to other treatments.